**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 65-year-old man (patient 1) and a 66-year-old man (patient 2) developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during treatment with rituximab, carboplatin, dexamethasone, etoposide, ibrutinib or ifosfamide \[*dosages and routes not stated*\].

Patient 1 had a history of cerebral relapse of diffuse large B-cell lymphoma (DLBCL) and arterial hypertension. Patient 2 had a history of mantle cell lymphoma and chronic renal insufficiency. Patient 1 started receiving treatment with rituximab, dexamethasone, etoposide, ifosfamide and carboplatin (RDeVIC) for several months. Patient 2 was in complete remission and was receiving maintenance therapy with rituximab and ibrutinib daily. Subsequently, both the patients developed SARS-CoV-2 infection. Two weeks before infection with SARS-CoV-2, they had received there last therapy cycle. Immunoglobulin G was decreased and B cells were completely depleted in both patients. Patient 1 was admitted to hospital at day 1 while patient 2 was admitted at day 4 following development of fever. Pharyngeal swabs identified SARS-CoV-2 RNA. On the day of admission, they did not had hypoxia and high fever persisted for the next 14--21 days. They developed hypoxia, on day 4 and day 9 of admission, respectively. Chest X-ray and thoracic CT of both patients demonstrated bilateral pulmonary peripheral ground glass infiltrates. On the day of there admission, inflammatory markers were elevated and significantly increased further over time. Due to elevated procalcitonin levels both of them received off-label anti-infective therapy with piperacillin/tazobactam. Despite all treatments, there condition deteriorated. Chest X-ray revealed progredient bilateral pulmonary infiltration. Due to progressive respiratory failure, they needed invasive ventilation following intubation on day 14. After persistent high temperature the plasma and cellular fraction of peripheral blood were analysed for SARS CoV-2 viraemia. A significant viraemia was detected with relatively low cycle threshold (Ct)-values in the plasma and cellular fraction by PCR of both patients. To further measure viraemia of patients, a standardised PCR assay was performed using a plasmid standard, which confirmed evidence of a massive viraemia at different time points. The virus levels further increased during the disease course with no indication of virus clearance at all. Both the patients died due to respiratory failure, at day 22 and day 26 after admission, respectively. Shortly before death, the viraemia was at it\'s peak. In patient 1, there was no sign of viral clearance at day 22 after development of first symptoms or at day 22 after first detection of SARS-CoV-2 RNA in pharyngeal swab. In patient 2, there was no sign of viral clearance at day 30 after development of first symptoms or at day 26 after first detection of SARS-CoV-2 RNA in pharyngeal swab.
